Results from a newly published study have found that a gene expression test called Corus CAD may be useful in helping physicians determine which patients are the best candidates for angiograms, and which can be spared the invasive procedure.
Developed by Palo Alto, Calif.-based CardioDX Inc., Corus CAD is commercially available and uses the RNA levels of 23 genes from a single blood sample to measure the likelihood that an individual patient has obstructive coronary artery disease.
In a 2-year study that appears in the Oct. 5, 2010 edition of the Annals of Internal Medicine, investigators at 39 hospitals in the United States analyzed results from Corus CAD tests that examined cells in the blood of 526 nondiabetic patients, and then compared them to outcomes from their angiograms (Ann. Intern Med. 2010; 153: 425-34).
“The critical question that we addressed – can the gene expression from white blood cells provide information about blockages of the coronary arteries? – was answered and validated in a select cohort who also underwent angiography,” principal investigator Dr. Eric Topol, who directs the La Jolla, Calif.-based Scripps Translational Science Institute, said in a prepared statement. “The findings may help our future ability to direct coronary angiography to the patients with real clinical need.”
CardioDX Inc. funded the trial.
— Doug Brunk (on Twitter@dougbrunk)